STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER
Analysis of latest trials, comparing treatment schemes including chemotherapy with anti-EGFR monoclonal antibodies or bevacizumab is presented in this article. The data in these trials is inconsistent, but detailed analysis of FIRE-3 trial allows to distinguish a wild-type RAS patient group that ben...
Main Author: | |
---|---|
Format: | Article |
Language: | Russian |
Published: |
“ABV-press” Publishing house”, LLC
2015-05-01
|
Series: | Тазовая хирургия и онкология |
Subjects: | |
Online Access: | https://ok.abvpress.ru/jour/article/view/122 |
_version_ | 1797759232654704640 |
---|---|
author | V. A. Gorbunova |
author_facet | V. A. Gorbunova |
author_sort | V. A. Gorbunova |
collection | DOAJ |
description | Analysis of latest trials, comparing treatment schemes including chemotherapy with anti-EGFR monoclonal antibodies or bevacizumab is presented in this article. The data in these trials is inconsistent, but detailed analysis of FIRE-3 trial allows to distinguish a wild-type RAS patient group that benefits most from chemotherapy with cetuximab or panitumumab as 1st line metastatic colorectal cancer treatment. A final analysis of this patient group in CALGB/SWOG 80 405 trial is pending. The RAS analysis is pivotal for choice of 1st line chemotherapy. |
first_indexed | 2024-03-12T18:41:27Z |
format | Article |
id | doaj.art-152a19bd2269424a9ca33792b46f07cd |
institution | Directory Open Access Journal |
issn | 2686-9594 |
language | Russian |
last_indexed | 2024-03-12T18:41:27Z |
publishDate | 2015-05-01 |
publisher | “ABV-press” Publishing house”, LLC |
record_format | Article |
series | Тазовая хирургия и онкология |
spelling | doaj.art-152a19bd2269424a9ca33792b46f07cd2023-08-02T07:48:52Zrus“ABV-press” Publishing house”, LLCТазовая хирургия и онкология2686-95942015-05-0151263610.17650/2220-3478-2015-1-26-36106STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCERV. A. Gorbunova0N.N. Blokhin Russian Cancer Research CenterAnalysis of latest trials, comparing treatment schemes including chemotherapy with anti-EGFR monoclonal antibodies or bevacizumab is presented in this article. The data in these trials is inconsistent, but detailed analysis of FIRE-3 trial allows to distinguish a wild-type RAS patient group that benefits most from chemotherapy with cetuximab or panitumumab as 1st line metastatic colorectal cancer treatment. A final analysis of this patient group in CALGB/SWOG 80 405 trial is pending. The RAS analysis is pivotal for choice of 1st line chemotherapy.https://ok.abvpress.ru/jour/article/view/122colorectal cancermonoclonal antibodiescetuximabpanitumumabantiangiogenic drug bevacizumabchemotherapy |
spellingShingle | V. A. Gorbunova STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER Тазовая хирургия и онкология colorectal cancer monoclonal antibodies cetuximab panitumumab antiangiogenic drug bevacizumab chemotherapy |
title | STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER |
title_full | STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER |
title_fullStr | STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER |
title_full_unstemmed | STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER |
title_short | STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER |
title_sort | study data of kras and ras unmutated wild type of colorectal cancer |
topic | colorectal cancer monoclonal antibodies cetuximab panitumumab antiangiogenic drug bevacizumab chemotherapy |
url | https://ok.abvpress.ru/jour/article/view/122 |
work_keys_str_mv | AT vagorbunova studydataofkrasandrasunmutatedwildtypeofcolorectalcancer |